Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-bevacizumab PET imaging of VEGF in relapsing multiple myeloma
2012-002335-28Phase 4Active
- Sponsor
- University Medical Center Groningen
- Start
- Jul 2012
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bevacizumab zirconium Zr-89 in multiple myeloma (MM), sponsored by University Medical Center Groningen. Primary endpoint: 89Zr-bevacizumab tracer uptake in multiple myeloma lesions. Started Jul 2012; status: active.
02
Drugs
bevacizumab zirconium Zr-89
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2012-002335-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002335-28.